Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche agreed to pay Ascidian Therapeutics $42 million upfront and up to $1.8 billion in milestones to discover and develop RNA exon editing therapies for…
Roche continued its push into genetic medicine with a deal worth up to $1.8 billion with Boston-based Ascidian Therapeutics. The pact gives Roche access to RNA…
Roche has entered into a collaboration and license agreement with Ascidian Therapeutics for the discovery and development of RNA exon editing therapeutics…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Ascidian Therapeutics entered collaboration and license agreement with Roche for discovery and development of RNA exon editing therapeutics targeting neurological diseases. $42M initial payment plus up to $1.8B in research, clinical and commercial milestones and royalties. Combines Ascidian's RNA exon editor technology with Roche's CNS delivery capabilities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Ascidian Therapeutics, Inc. (this deal) | 2024 | $1.8B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2024 deals · Roche Holding AG deals · Neurology deals